Zobrazeno 1 - 10
of 60
pro vyhledávání: '"R L, Comis"'
Autor:
R. L. Comis
Publikováno v:
Annals of Oncology. 3:S63-S67
Summary Etoposide has been in clincial trials for over 2 decades. From the inception of these investigations, both the oral and intravenous routes have been employed. The oral route has been shown to be convenient, sage, and effective in The trials o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c335197bbdfc15c23eaeca8ee51e596
https://doi.org/10.1093/annonc/3.suppl_3.s63
https://doi.org/10.1093/annonc/3.suppl_3.s63
Autor:
R. L. Comis, David Goldstein, D. C. Tormey, M. Shiraki, Ernest C Borden, J. E. Harris, B. Cheuvart, D. L. Trump
Publikováno v:
American Journal of Clinical Oncology. 13:420-423
As part of the Eastern Cooperative Oncology Group program for the assessment of new drugs in sarcomas, a Phase II trial of carboplatin was performed in patients who had received no more than one prior chemotherapy regimen. A total of 50 patients rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be0de31cc4e14e7477b9a0b2f13997f6
https://doi.org/10.1097/00000421-199010000-00011
https://doi.org/10.1097/00000421-199010000-00011
Autor:
R L, Comis, R S, Finley
Publikováno v:
Seminars in oncology. 26(6 Suppl 18)
In recent years significant advances have been made in the treatment of metastatic non-small cell lung cancer. These advances have been due to both the discovery of new, more active drugs and an enhanced understanding of the biology of the disease, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::79f9fe9b5167019a929a7985c37d219b
https://pubmed.ncbi.nlm.nih.gov/10892574
https://pubmed.ncbi.nlm.nih.gov/10892574
Autor:
A, Kovatich, D M, Friedland, T, Druck, P, Hadaczek, K, Huebner, R L, Comis, W, Hauck, P A, McCue
Publikováno v:
Cancer. 83(6)
The origins of and interrelations between low grade and high grade neuroendocrine lung tumors, typical and atypical carcinoids, and small cell lung carcinoma (SCLC) have not been elucidated. Karyotypic and molecular genetic studies have demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::034e9bf65a4110ce767d00bef5dc664e
https://pubmed.ncbi.nlm.nih.gov/9740075
https://pubmed.ncbi.nlm.nih.gov/9740075
Publikováno v:
Oncology (Williston Park, N.Y.). 12(1 Suppl 2)
Despite advances in the treatment of small-cell lung cancer during the 1970s, with the use of combination chemotherapy, and in the 1980s, with the combination of etoposide and cisplatin plus concurrent radiation therapy, treatment success seems to ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9ccb58ffcbb7b00b1275d5ea5d2d8a85
https://pubmed.ncbi.nlm.nih.gov/9516611
https://pubmed.ncbi.nlm.nih.gov/9516611
Autor:
C J, Langer, W J, Curran, S M, Keller, R B, Catalano, S, Litwin, K B, Blankstein, N, Haas, S N, Campli, R L, Comis
Publikováno v:
The cancer journal from Scientific American. 2(2)
Patients with locally advanced, initially unresectable non-small cell lung cancer (NSCLC) have a median survival time of 9 to 11 months, a 2-year survival rate of 13%, and a long-term survival rate of 5% to 7% when treated with radical thoracic radia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2b56454b81ea70cb8fa088a6a34d459d
https://pubmed.ncbi.nlm.nih.gov/9166503
https://pubmed.ncbi.nlm.nih.gov/9166503
Perioperative therapy of non-small cell lung cancer: a review of adjuvant and neoadjuvant approaches
Autor:
D M, Friedland, R L, Comis
Publikováno v:
Seminars in oncology. 22(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::da70ff5e6bdcc7a856d2bd3893f10d23
https://pubmed.ncbi.nlm.nih.gov/8539633
https://pubmed.ncbi.nlm.nih.gov/8539633
Autor:
C J, Langer, J C, Leighton, R L, Comis, P J, O'Dwyer, C A, McAleer, C A, Bonjo, P F, Engstrom, S, Litwin, S, Johnson, R F, Ozols
Publikováno v:
Seminars in oncology. 22(4 Suppl 9)
A phase II trial of combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin included 54 chemotherapy-naive patients with advanced non-small cell lung cancer. Eligibility mandated Eastern Cooperative Oncology Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::93f68b8b0dae3108acaba3e1d4b46476
https://pubmed.ncbi.nlm.nih.gov/7544025
https://pubmed.ncbi.nlm.nih.gov/7544025
Autor:
R L, Comis
Publikováno v:
Seminars in oncology. 21(5 Suppl 12)
Cisplatin is one of the most important anticancer drugs yet developed. It proved critical in the development of curative programs for testicular cancer and in life-prolonging regimens for such diseases as small cell lung cancer, ovarian cancer, and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3a34736d48177c4e097066783183f466
https://pubmed.ncbi.nlm.nih.gov/7992062
https://pubmed.ncbi.nlm.nih.gov/7992062
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 270(3)
Ethacrynic acid (EA) is an inhibitor of the glutathione S-transferases (GSTs), a family of detoxification enzymes the expression of which has been associated with resistance to several classes of anticancer drugs. We performed a two-way randomized cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::76be43c190f26cbc16c3457146372d6d
https://pubmed.ncbi.nlm.nih.gov/7932170
https://pubmed.ncbi.nlm.nih.gov/7932170